

1 **The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta**
2 **virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA**
3 **vaccine boost are comparable to those after double immunisation with mRNA vaccines**

4 Ruben Rose ^{1,†}, Franziska Neumann ^{2,†}, Olaf Grobe ², Thomas Lorentz ², Helmut Fickenscher ¹,
5 Andi Krumbholz ^{1,2,*}

6 1 Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum
7 Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany

8 2 Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany

9 * Correspondence: krumbholz@infmed.uni-kiel.de; Tel.: +49-431-22010131

10 † These first authors contributed equally

11 **Abstract**

12 **Background:** The humoral immune response after primary immunisation with a SARS-CoV-2 vector
13 vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost
14 (Pfizer/BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody
15 response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2).

16 **Methods:** Sera from 59 vaccinees were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) and virus-
17 neutralising antibodies (VNA) with four IgG assays, a surrogate neutralisation test (sVNT), and a Vero
18 cell-based neutralisation test (cVNT) using the B.1.1.7 variant of concern (VOC; alpha) as antigen.
19 Investigation was done before and after heterologous (n=31 and 42) or homologous booster
20 vaccination (AZD1222/AZD1222, n=8/9; BNT162b2/BNT162b2, n=8/8). After the second immunisation,
21 26 age and gender matched sera (AZD1222/mRNA, n=9; AZD1222/AZD1222, n=9;
22 BNT162b2/BNT162b2, n=8) were also tested for VNA against VOC B.1.617.2 (delta) in the cVNT. The
23 strength of IgG binding to separate SARS-CoV-2 antigens was measured by avidity.

24 **Results:** After the first vaccination, prevalence of IgG directed against (trimeric) SARS-CoV-2 spike (S)-
25 protein and its receptor-binding domain (RBD) varied from 55-95 % (AZD1222) to 100% (BNT162b2),
26 depending on the vaccine used and the SARS-CoV-2 antigen used. The booster vaccination resulted in
27 100 percent seroconversion and appearance of highly avid IgG as well as VNA against VOC B.1.1.7. The
28 results of the anti-SARS-CoV-2 IgG tests showed an excellent correlation to the VNA titres against this
29 VOC. The agreement of cVNT and sVNT results was good. However, the sVNT seems to overestimate
30 non and weak B.1.1.7-neutralising titres. The mean anti-SARS-CoV-2 IgG and B.1.1.7-neutralising titres
31 were significantly higher after heterologous vaccination compared to the homologous AZD1222
32 scheme. If VOC B.1.617.2 was used as antigen, significantly lower mean VNAs were measured in the
33 cVNT, and three (33.3%) vector vaccine recipients had a VNA titre <1:10.

34 **Conclusions:** The heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-
35 SARS-CoV-2 IgG and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination
36 scheme. Irrespectively of the chosen immunisation regime, highly avid IgG antibodies can be detected

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 just two weeks after the second vaccine dose indicating the development of a robust humoral
38 immunity. The observed reduction in the VNA titre against VOC B.1.617.2 is remarkable and may be
39 attributed to a partial immune escape of the delta variant.

40 **Keywords:** COVID-19; vaccination schemes; immunoglobulin G; maturity process; virus variants of
41 concern; virus-neutralisation

42

43 **Background**

44 Since spring 2020 the pandemic caused by the *severe acute respiratory syndrome coronavirus 2* (SARS-
45 CoV-2) [1] is ongoing and represents a global challenge. The availability of safe and effective
46 vaccinations are seen as one of the most important pillars in containing the pandemic [2, 3]. Within a
47 few months, the intensive research activities led to the development of several highly effective SARS-
48 CoV-2 vaccines [4, 5, 3]. In addition to the induction of cellular immunity, their administration should
49 stimulate the formation of virus-neutralising antibodies (VNA) that bind to epitopes of the viral spike
50 (S)-protein and its receptor binding domain (RBD) and, thus, prevent the cells from being infected [6,
51 7, 3].

52 Four SARS-CoV-2 vaccines have received conditional approval in the European Union. These vaccines
53 are based on two different technologies [8]. For the messenger ribonucleic acid (mRNA) vaccines from
54 Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), the genetic information for the S-protein
55 was genetically optimised and the mRNA was packaged in liposomes. After inoculation, the muscle
56 cells directly expressed this stable and highly immunogenic viral surface protein [2, 6]. In vector
57 vaccines, replication-deficient human (Ad26.CO2; Janssen) or chimpanzee adenoviruses (ChAdOx1
58 nCoV-19/AZD1222, Vaxzevria; AstraZeneca, hereinafter referred to as AZD1222) are used to introduce
59 the genetic information of the SARS-CoV-2 S-protein into the cells, followed by transcription of
60 deoxyribonucleic acid into mRNA and expression of the S-protein [2, 6].

61 Due to the widespread use of these vaccines, rare and sometimes unexpected side effects have been
62 reported. Particularly noteworthy are cases of immune thrombotic thrombocytopenia, which
63 predominantly occurred in women under 50 years of age within one month after the initial vaccination
64 with AZD1222 [5]. Many of these patients developed cerebral sinus venous thrombosis or splanchnic
65 vein thrombosis and presented antibodies to platelet factor 4 but without previous exposure to
66 heparin [5]. Due to this rare but serious side effect, AZD1222 is no longer unreservedly recommended
67 by the Standing Vaccination Commission (STIKO) of the Robert Koch Institute for individuals under 60
68 years of age. The STIKO suggests that a vaccination with AZD1222 that has already started should be
69 completed with an mRNA vaccine [9, 10]. Due to the sharp increase in the delta variant of concern
70 (VOC; Pango-lineage [11] B.1.617.2) in Germany, the STIKO has revised its recommendations once
71 more. Since July 1st 2021, all AZD1222 first vaccinated persons have been recommended to complete
72 the second vaccination with an mRNA vaccine [12]. Animal experiments indicated very good humoral
73 and cellular immunity after heterologous vaccination [13, 14]. There is, however, so far limited
74 knowledge on the benefit of the heterologous vaccination scheme in humans. First results indicated a

75 higher prevalence of short-lived side effects following the heterologous boost dose compared to the
76 homologous counterpart [15]. Meanwhile, a few studies have been published for the immunogenicity
77 of the AZD1222/mRNA vaccine regimen [16-21].

78 In this report, we compare the SARS-CoV-2 specific immunoglobulin G (IgG) response after
79 heterologous immunisation with that elicited by homologous vaccination schedules. We also focus on
80 the developing anti-SARS-CoV-2 IgG avidity as a parameter for IgG maturity and binding strength.
81 Finally, we use various methods to investigate the development of VNA against two prevalent VOCs.
82 Therefore, humoral immunity induced by vaccines is being extensively studied. We believe that the
83 results obtained in this study will help to better understand the effects and possibly benefits of a
84 heterologous vaccination regimen.

85

86 **Methods**

87 The anti-S and anti-RBD IgG response after heterologous immunisation with a SARS-CoV-2 vector
88 vaccine as prime and an mRNA vaccine as boost was compared to that after homologous vaccination
89 with vector or mRNA vaccines. This setting also includes monitoring of IgG avidity and of virus-
90 neutralising capacities. Forty-seven female and twelve male vaccinees with a median age of 31 years
91 (age span 18 – 61 years) were recruited for this study and gave their informed consent. Forty-two of
92 them received a heterologous immunisation scheme (N=41, AZD1222/BNT162b2; N=1,
93 AZD1222/mRNA-1273), while nine and eight vaccinees received a homologous scheme of the vector
94 vaccine AZD1222 or the mRNA vaccine BNT162b2, respectively. The first blood sample was taken
95 immediately before the second vaccination and the second about two weeks later. For several
96 individuals no serum was available before or after the booster vaccination (Table 1). The ethics
97 committee of the medical faculty of the Christian-Albrechts-Universität zu Kiel (Kiel, Germany)
98 approved the study design (D467/20, 16.04.2020, amendment 02.02.2021). We examined the early
99 humoral immune response (other samples obtained a few days to weeks after the initial immunisation
100 with AZD1222) of most of the subjects in a previous study. In addition, sera obtained from three
101 vaccinees after the initial immunisation with BNT162b2 (N=2) and AZD1222 (N=1) have already been
102 tested in frame of the previous study [22]. In this respect, we consider it justified to include these
103 individuals (and few sera) in the present report and to demonstrate the results before and after the
104 booster vaccination.

105 *Anti-SARS-CoV-2 specific IgG immunoassays*

106 The sera were tested with the SERION ELISA agile SARS-COV-2 IgG assay (S-protein as antigen; Institut
107 Virion\Serion GmbH, Würzburg, Germany) and the Abbott SARS-CoV-2 IgG II Quant assay (RBD as
108 antigen; Abbott, Wiesbaden, Germany) as described previously [22]. In addition, the LIAISON® SARS-
109 CoV-2 Trimeric S IgG assay was included as a further assay on a LIAISON® XL system (both Diasorin
110 S.p.A, Saluggia, Italy). According to the manufacturer, this quantitative chemiluminescence
111 immunoassay detects IgG directed against the trimeric S-protein and has an excellent clinical sensitivity
112 and specificity of 98.7% and 99.5%, respectively. The high diagnostic value of this test has also been

113 demonstrated in a recent seroprevalence study [23]. The results of the three IgG assays were given in
114 Binding Antibody Units (BAU) per milliliter (ml), using the manufacturer's conversion factors, which
115 were based on measurements of the WHO International Standard Anti-SARS-CoV-2 Immunoglobulin
116 (NIBSC code 20-136) [24]. As in our previous studies, we generally rate borderline test results as
117 positive [25, 22].

118 *Anti-SARS-CoV-2 IgG immunoblots including measurement of IgG avidities*

119 All sera were tested with and without avidity reagent in the *recomLine* SARS-CoV-2 IgG assay (Mikrogen
120 GmbH, Neuried, Germany) as reported previously [25, 22]. The strength of SARS-CoV-2 antigen binding
121 against the S1-and RBD-subunits of the S-protein and against the nucleoprotein (NP, if detectable) was
122 assigned to the categories low (= 1), intermediate (= 2), and high (= 3) [22].

123 *Measurement of SARS-CoV-2-neutralising antibodies*

124 The sera were examined for their virus-neutralising capacities. First, a surrogate assay was used (TECO®
125 SARS-CoV-2 Neutralisation Antibody ELISA; TECOmedical AG, Sissach, Switzerland). In this competitive
126 assay, the human angiotensin-converting enzyme 2 (ACE-2) was attached to the solid phase while
127 peroxidase-conjugated RBD was present in the liquid phase. If the human serum contained RBD-
128 specific antibodies, binding of RBD to ACE-2 was prevented. Hence, after washing steps the color
129 reaction turned out to be weaker compared to a RBD-antibody-free serum sample. According to the
130 manufacturer, it is assumed from an inhibition of 20% that VNA are present [22].

131 Second, dilutions of each serum were tested in triplicate in a laboratory-developed Vero cell-based
132 neutralisation assay (cVNT). This 96-well format cVNT uses two own SARS-CoV-2 isolates (alpha, VOC
133 B.1.1.7; delta, VOC B.1.617.2) obtained after cultivation of clinical samples in Vero cells as described
134 previously [26]. A dilution >1:10 was considered likely protective [25, 22].

135 *Data evaluation and statistical calculations*

136 Data were statistically analysed by help of the GraphPad Prism version 9.1.2 software (GraphPad
137 Software, San Diego, CA, USA). In most cases, the Kruskal-Wallis test, an adjusted, non-paired and non-
138 parametric test was applied. The Wilcoxon test, a paired non-parametric test, was chosen to compare
139 the mean VNA titre differences against VOC B.1.1.7 and VOC B.1.617.2. The level of significance was
140 generally set at 0.05. Furthermore, we calculated the Pearson correlation coefficient r to demonstrate
141 the linear correlation between separate data sets. We used a simple logistic regression to determine
142 the probability of detecting VNA with our cVNT as a function of the anti-SARS-CoV-2 IgG or sVNT
143 results.

144

145

146 **Results**

147 *Composition of the study groups*

148 This study included 59 individuals. Nine and eight of them received a homologous immunisation with
149 AZD1222 or BNT162b2, respectively, while 42 received a heterologous vaccination. The composition
150 of the study groups including median age, age range, gender and median time of blood collection in
151 days is shown in Table 1.

152 **Table 1.** Individuals included in this study


Study groups	Number of individuals after 1 st /2 nd vaccination	Median age in years	Age span in years	Gender (female/male)	Time (median) from 1 st /2 nd vaccination up to 1 st /2 nd serum sampling in days
<i>Heterologous vaccination scheme</i>					
AZD1222/BNT162b2	30/41	27	18-56	33/8	69/16
AZD1222/BNT162b2†	-/9	43	23-56	7/2	-/14
AZD1222/mRNA-1273	1/1	45	45-45	1/0	64/14
<i>Homologous vaccination scheme</i>					
AZD1222†	8/9	41	23-61	6/3	69/16
BNT162b2†	8/8	35	23-51	7/1	34/14

153 † After the second vaccination, several sera were also tested for presence of virus-neutralising antibodies against the SARS-
154 CoV-2 delta variant of concern (B.1.617.2). For this purpose, individuals from the group of heterologous vaccinations whose
155 age and gender largely corresponded to those with homologous vaccinations were chosen.

156 After the first immunisation, all individuals who received an mRNA vaccine developed anti-(trimeric)-
157 S and anti-RBD-IgG. The vaccinees who received the AZD1222 had a prevalence of 55.3 % (anti-S IgG),
158 76.3% (anti-trimeric S IgG) and 94.7% (anti-RBD IgG), respectively. After administration of the second
159 dose, the IgG prevalence reached 100% in all groups. The mean anti-SARS-CoV-2 IgG titres varied
160 between 39.9 BAU/ml (anti-S IgG; first vaccination in the AZD1222/mRNA group) to 6584 BAU/ml (anti-
161 trimeric S IgG; second vaccination in the BNT162b2/BNT162b2 group). After the second vaccine dose,
162 an increase in mean anti-SARS-CoV-2 IgG titres was observed in all three study groups and in all assays.
163 Compared to the mean anti-SARS-CoV-2 IgG titres after the vector vaccine AZD1222 was administered
164 twice, the corresponding titres were 7 to 10 times higher after a heterologous vaccination and even
165 10 to 15 times higher according to the homologous BNT162b2 vaccination scheme (Figure 1).

166

167




168

169 **Figure 1:** Anti-SARS-CoV-2 immunoglobulin G (IgG) response in Binding Antibody Units (BAU) per milliliter (ml) after first (1;
170 empty circles) and second (2; filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid
171 (mRNA)-based vaccines BNT162b2 or mRNA-1273. The cut-offs for positivity (including borderline results) of anti-trimeric
172 spike (S) IgG assay (A), of the anti-S IgG assay (B), and of the anti-receptor binding domain (RBD) IgG assay (C), respectively,
173 are marked by dashed lines. Ns: non-significant; *: p < 0.05; **: p < 0.01; ****: p < 0.0001 (Kruskal-Wallis test).

174 Next, we examined the development of anti SARS-CoV-2 IgG avidity in an immunoblot. After the first
175 vaccination, the mean avidity index was in the low to intermediate range. In contrast, high avidities
176 were consistently observed after administration of the second vaccine dose (Figure 2). None of the
177 vaccinees showed an IgG reactivity against the NP in the immunoblot (data not shown).

178




179

180 **Figure 2:** Development of anti-SARS-CoV-2 immunoglobulin G avidities after first (1; empty circles) and second (2; filled circles)
 181 immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or
 182 mRNA-1273. The measured IgG avidities were assigned to the three categories low (1), intermediate (2) and high (3) and a
 183 mean avidity index was calculated per individual serum. Ns: non-significant; *: $p < 0.05$; **: $p < 0.01$; ****: $p < 0.0001$ (Kruskal-
 184 Wallis test).

185 The virus-neutralising properties of the sera were examined with two different assays. A so-called
 186 surrogate neutralisation test was used to investigate the extent to which the anti-RBD antibodies that
 187 may be present in the serum are able to prevent the binding of this S-protein subunit to the human
 188 receptor ACE2. In addition, a laboratory-developed virus-neutralisation test was used, which is based
 189 on a VOC B.1.1.7 strain as the antigen. While the majority of the sera in the sVNT were already to be
 190 regarded as SARS-CoV-2 neutralising after the first vaccination, these samples did not yet show any
 191 corresponding properties in the cVNT. With both methods, however, an increase in the level of VNA
 192 could be detected after a second vaccination. There were also marked differences between the three
 193 vaccination groups, both in the degree of inhibition (sVNT) and in the level of VNA titres (cVNT).
 194 Vaccinees who had received the vector vaccine only had 13- and 11-fold lower geometric mean VNA
 195 titres (1:47) compared to individuals immunised heterologously with AZD1222/mRNA (1:608) or
 196 homologously with BNT162b2 (1:538), respectively. However, the mean % inhibition of sVNT reached
 197 about the same level in all three groups (Figure 3). The quantitative results of the anti-SARS-CoV-2 IgG
 198 assays showed an almost perfect correlation to the VNA titres using VOC B.1.1.7 as antigen in the cVNT
 199 (Pearson correlation coefficient of 0.89 to 0.91; Figure 4 A-C). In addition, from a certain anti-SARS-
 200 CoV-2 IgG titer, it could be assumed with a high degree of probability that VNA are present. The anti-
 201 SARS-CoV-2 IgG BAU/ml titres required for this differed between the three assays, but were all in the
 202 three-digit range (Figure 4 D-F). The correlation between the measured values of cVNT (VOC B.1.1.7 as

203 antigen) and sVNT was somewhat less pronounced (Pearson correlation coefficient r of 0.84). It is
204 noticeable that especially non-neutralising sera ($\leq 1:10$) were overestimated in the sVNT. This is
205 evidenced by the fact that the cut-off set by the manufacturer was only associated with a 4 %
206 probability of detecting VNA in our cVNT (Figure 5).

207




208

209

210 **Figure 3:** Development of SARS-CoV-2 neutralising antibodies (VNA) after first (1; empty circles) and second (2; filled circles)
211 immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or
212 mRNA-1273. A surrogate neutralisation assay (A) and a Vero-cell based virus-neutralisation test (cVNT) using the SARS-CoV-
213 2 variant of concern B.1.1.7 (alpha) strain (B) were applied to measure the VNAs. The assay cut-offs are indicated by dashed
214 lines. Ns: non-significant; *: $p < 0.05$; **: $p < 0.01$; ****: $p < 0.0001$ (Kruskal-Wallis test).

215




216

217

218 **Figure 4:** Anti-SARS-CoV-2 immunoglobulin G (IgG) response in Binding Antibody Units (BAU) per milliliter (ml) after first
 219 (open circles) and second (filled circles) immunisation with the vector vaccine AZD1222 (green), the messenger ribonucleic
 220 acid (mRNA)-based vaccine BNT162b2 (blue) and after a heterologous vaccination scheme, starting with AZD1222, followed
 221 by an mRNA-based vaccine boost (BNT162b2 or mRNA-1273; red) with regard to the detection of virus-neutralising antibodies
 222 (VNA). The latter were measured in a Vero cell-based neutralisation test (cVNT) using the SARS-CoV-2 variant of concern
 223 B.1.1.7 (alpha). Cut-off values for positivity of the anti-trimeric spike (S) IgG assay (A), anti-S IgG assay (B) and anti-receptor
 224 binding domain (RBD) IgG assay (C), respectively, and the cVNT cut-off value for presence of VNA are indicated by dashed
 225 lines. The Pearson correlation coefficients r of $\log(\text{reciprocal titre})$ were calculated with 0.89, 0.89, and 0.91, respectively. The
 226 probability of detecting VNA at a given BAU/ml in the anti-SARS-CoV-2 IgG assays was calculated by logistic regression (D-F):
 227 VNA were present in 95% of samples when titres of 886 BAU/ml (anti-trimeric S IgG), 323 BAU/ml (anti-S IgG), and 448 BAU/ml
 228 (anti-RBD IgG) were measured (green dashed lines; 95% confidence intervals 59.4 to 99.6%). Vertical black dashed lines
 229 represent the threshold values set by the manufacturers of the antibody assay; red dashed lines represent the BAU/ml values
 230 (anti-trimeric S IgG: 350 BAU/ml; anti-S IgG: 119 BAU/ml; anti-RBD IgG: 174 BAU/ml) with a 50% probability of VNA detection.

231




232

233

234 **Figure 5:** Correlation of the surrogate neutralisation test (sVNT) results with results obtained by the laboratory developed
 235 Vero-cell based virus-neutralisation test (cVNT) using a B.1.1.7 strain as antigen **(A)**. The Pearson correlation coefficient r of
 236 $\log(\text{reciprocal titre})$ was calculated with 0.84; empty circles; first vaccination; filled circles: second vaccination; red:
 237 heterologous vaccination with AZD1222/mRNA; green: homologous vaccination with AZD1222; blue: homologous vaccination
 238 with BNT162b2. Probability of detecting virus-neutralising antibodies (VNA) with the cVNT at a given % inhibition of sVNT
 239 calculated by logistic regression **(B)**; e.g. at 20% inhibition (black dashed line), 63 % inhibition (red dashed line), and at 87%
 240 inhibition of sVNT (green dashed line), the probabilities of detecting VNA with cVNT are 4% (95% confidence interval (CI) 1
 241 %-16%), 50% (95% CI 34 %-66%) and 85% (95% CI 73 %-92%), respectively.

242

243 A subset of age-and gender matched sera (Table 1) obtained after the second immunisation were also
 244 tested in the cVNT for presence of VNA against VOC B.1.617.2 (delta). In comparison to B.1.1.7, all
 245 three vaccination groups exhibited significantly lower mean VNA titres (AZD1222/BNT162b2: 838.0 vs.
 246 89.8, 9.3-fold lower; AZD1222/AZD1222: 47.3 vs. 9.0, 5.3-fold lower; BNT162b2/BNT162b2: 538.2 vs.
 247 160.0, 3.4-fold lower) when B.1.617.2 is used as the antigen. If the vaccination schedule is used as a
 248 basis, those vaccinated homologously with the vector vaccine had significantly lower mean VNAs than
 249 those homologously vaccinated with BNT162b2. This difference was also found for the heterologous
 250 vaccination regime. In contrast, the mean VNAs between those vaccinated homologously with
 251 BNT162b and those vaccinated heterologously (AZD1222/BNT162b2) exhibited no measurable
 252 difference (Figure 6).



253

254 **Figure 6:** Presence of virus-neutralising antibodies (VNA) against the SARS-CoV-2 variants of concern B.1.1.7 (alpha) and
 255 B.1.617.2 (delta) after the second immunisation. Sera from 26 age and gender matched individuals who received a
 256 heterologous (AZD1222/BNT162b2, n=9) or a homologous vaccination scheme (AZD1222/AZD1222, n=9;
 257 BNT162b2/BNT162b2, n=8) were tested (see Table 1). An individual VNA titre > 1:10 was defined as neutralising in our Vero
 258 cell-based virus neutralisation test (cVNT). † The significance of the mean VNA titre differences against B.1.1.7 and B.1.617.2
 259 were calculated using the Wilcoxon test (**: p < 0.01; ***: p < 0.001). ‡ Comparison of the mean VNA titre differences
 260 achieved with different immunisation schemes against B.1.617.2 (Kruskal-Wallis test; ns: not significant; *: p < 0.05; ****: p
 261 < 0.0001).

262

263 Discussion

264 Due to the rare but serious side effects after administration of the vector vaccine, in spring 2021 the
 265 STIKO recommended that people under the age of 60 should complete vaccinations that had already
 266 been started with a vector vaccine with an mRNA vaccine [9, 10]. This recommendation was extended
 267 on July 1st, 2021 to all who had already received a primary vaccination with AZD1222 [12]. In the first
 268 quarter of this year, however, only a few animal experimental data were available on the
 269 immunological outcome of the proposed heterologous vaccination scheme [13, 14]. Several studies
 270 have now appeared on the immunogenicity of the heterologous vaccination scheme in humans [16,
 271 21, 17-20].

272 In this report, we compared the development of the humoral immune response after homologous and
 273 heterologous vaccination with different methods. To the best of our knowledge, we are one of the first

274 research groups to investigate the anti-delta VOC neutralising effect of sera after completing the
275 heterologous immunisation regime.

276 After the first vaccination, the majority of individuals developed anti-trimeric-S, -S, and -RBD IgG
277 antibodies, respectively. However, their titres varied between the three study groups. The results are
278 in line with our previous study [22]. It is evident that the anti-SARS-CoV-2 IgG titres are not comparable
279 between the three assays either. This is probably due to the different antigen preparations. In this
280 respect, from our point of view, titre comparisons are only possible if they have been measured with
281 the same assay.

282 The second immunisation resulted in higher titres in all three groups. It was noticeable that
283 significantly higher anti-SARS-CoV-2 IgG titres were detected after a second vaccination with an mRNA
284 vaccine than after the vector vaccine AZD1222 was administered again. The increase in anti-S and anti-
285 RBD IgG titres after a second vaccination with an mRNA vaccine confirms our previous study. Due to
286 the recommended vaccination interval of 10 to 12 weeks, we did not yet have any data on the
287 development of the SARS-CoV-2-specific IgG antibodies after the second administration of a vector
288 vaccine [22]. The lack of NP-specific IgG antibodies in all vaccinees can be interpreted as an indication
289 that they had no SARS-CoV-2 infection and were therefore to be regarded as immunologically naive
290 before immunisation [22]. It is known that vaccinations lead to particularly high anti-SARS-CoV-2 IgG
291 titres in convalescents [27]. For these individuals, the recommendation is that they should receive a
292 vaccine dose about six months after they have been infected [10].

293 After the first vaccination nearly all vaccinees exhibited only low to intermediate avid anti-SARS-CoV-
294 2 IgG, while after the second vaccine dose IgG of high avidity appeared in all cases. These results
295 confirm and expand the existing knowledge on the development of highly avid anti-SARS-CoV-2 IgG
296 after a second vaccination with an mRNA vaccine [28]. In line with this, VNA > 1:10 against the
297 previously prevalent SARS-CoV-2 VOC B.1.1.7 (alpha) were observed after second immunisation which
298 confirms our recent study [22]. Marked differences in mean VNA titres were observed between
299 individuals re-vaccinated with an mRNA vaccine and those re-vaccinated with a vector vaccine which
300 is in accordance to animal experiments [13]. The anti-SARS-CoV-2 IgG titres obtained with three
301 preparations of the viral S-protein correlated well with the presence and level of VNA using B.1.1.7 as
302 the antigen in our cVNT. This observation is in line with a recently published study from Finland [29]
303 and suggests that these standardised and easy-to-perform commercial tests are useful for
304 demonstrating vaccination success. Anti-SARS-CoV-2 IgG titres that indicate the presence of VNA
305 cannot, however, be defined across the board. These depend on the cVNT and the viral antigen used
306 in it. Basically, the sVNT also showed the titre increase and evaluated all sera as virus-neutralising after
307 the second vaccination. However, it is again noticeable that sera that are not or only weakly SARS-CoV-
308 2-neutralising in the in-house cVNT are already evaluated as neutralising in the sVNT. This result
309 supports our previous suggestion to raise the cut-off of the sVNT [22]. Compared to the admittedly
310 very conservative in-house cVNT, a cut-off of over 80% would be desirable. Due to the lack of
311 standardisation of the widespread cVNTs for the detection of VNA against SARS-CoV-2, this
312 recommendation only applies to our laboratory and cannot be generalised.

313 From our point of view, a particularly interesting point is the significantly reduced capacity for
314 neutralising the SARS-CoV-2 delta variant (VOC B.1.617.2) *in vitro* using a cVNT. We observed this in all
315 26 age and gender matched individuals regardless of the immunisation regime. In addition, three of
316 nine vaccinees who had received two doses of AZD1222 presented low or undetectable VNA against
317 this VOC, which is considered to be 60% more transmissible than alpha [30]. The SARS-CoV-2 delta VOC
318 is known to have accumulated a number of mutations in the S-protein. These enable continued good
319 binding to the cellular ACE2 receptor, but at the same time lead to the viral S-protein being less
320 efficiently recognised by antibodies [30]. The significantly lower VNA titres compared to the alpha VOC,
321 which we and others [30, 31] observed, corroborate the suspicion of an immunescape of the delta
322 VOC. Based on our VNA data for B.1.1.7, it can be assumed that a single vaccination is not sufficient to
323 induce measurable VNA against B.1.617.2.

324 The results presented by us on the antibody response after heterologous SARS-CoV-2 vaccination are
325 consistent with the few available clinical studies [17, 19, 21, 16, 18, 20]. In June 2021, a randomised
326 study from Spain has already demonstrated that the heterologous vaccination scheme is suitable for
327 generating a robust immune response. Unfortunately, this very extensive work did not include a
328 control group of individuals who received two immunisations with the vector vaccine [21]. A recent
329 preprint reports significant higher anti-S antibody titres in a group of 26 individuals who first received
330 an AZD1222 vaccination followed by re-vaccination with BNT162b2 compared to 14 individuals that
331 were vaccinated twice with BNT162b2. However, these results were obtained with a total antibody
332 assay which does not discriminate between IgG and acute phase immunoglobulin M. Furthermore,
333 markedly higher VNA titres were observed in the AZD1222/BNT162b2 group using chimeric vesicular
334 stomatitis viruses carrying the S-proteins of SARS-CoV-2 VOCs B.1.1.7 (alpha) or B.1.351 (beta),
335 respectively, as antigens. However, data after homologous vaccination with the vector vaccine are
336 missing in this preliminary report [16]. In another investigation [18], differences in the anti-S IgG and
337 VNA titres were not observed after heterologous vaccination (AZD1222/mRNA) or after homologous
338 vaccination with an mRNA vaccine. In contrast, both parameters were significantly lower after
339 homologous vaccination with the vector vaccine. These results are in agreement with our data even if
340 only one IgG assay and one sVNT were used by this research group [18]. The results of a single-blind
341 randomised British study, in which the four possible vaccine combinations of AZD1222 and BNT162b2
342 were compared with one another, are very interesting and promising. These researchers report about
343 9-fold higher mean anti-S IgG titres in sera from heterologous AZD1222/BNT162b2 vaccinees
344 compared to individuals immunised twice with AZD1222 [19] which is largely in accordance to our
345 results. In a study from Sweden, markedly higher anti-S and anti-RBD IgG titres were observed after
346 heterologous vaccination (AZD1222/mRNA-1273) compared to the homologues AZD1222 scheme. In
347 line with this the occurrence of significantly higher VNA titres both against a wild-type SARS-CoV-2 and
348 against a VOC B.1.351 (beta) strain were demonstrated for these vaccinees [20]. One investigation
349 reports the development of high IgG avidity after completion of a homologous (AZD1222/AZD1222;
350 BNT162b2/BNT162b2) or heterologous SARS-CoV-2 (AZD1222/BNT162b2) immunisation scheme.
351 While there were no qualitative differences in the development of IgG avidity between both groups,
352 the AZD1222/BNT162b2 vaccinees developed a significantly higher relative avidity index [17]. In our

353 assay we cannot investigate such gradual differences. Furthermore, the authors report markedly lower
354 anti-SARS-CoV-2 IgG and VNA (against VOCs alpha and beta) titres in the AZD1222/AZD1222 group
355 [17].

356 It is not yet sufficiently clear why homologous vaccination with the AZD1222 vector vaccine leads to
357 lower anti-SARS-CoV-2 IgG and VNA titres. A possible explanation could be the immune response to
358 the adenovirus vector backbone (so called “antivector immunity” [3]).

359 The work presented by us contributes to a better understanding of the humoral immunogenicity of
360 the heterologous SARS-CoV-2 vaccination regimen. With various assays we monitored the
361 development of anti S-specific IgG antibodies and make statements about their binding-strength as an
362 expression of maturity. In addition, with a commercial and an in-house test, we showed that VNA can
363 be detected after the second vaccination and that VNA titres vary in dependence of the viral antigen.

364 Important limitations of our report are (i) the heterogeneity of the study groups, (ii) the small group
365 size of individuals who received a homologous vaccination scheme, (iii) the subjects, who are
366 predominantly in younger to middle adulthood, (iv) the lack of information on the durability of the
367 detected antibodies, and (v) the missing consideration of cellular and innate immunity after
368 immunisation. Therefore, among other things, no statements can be made from our data about the
369 need for further booster vaccinations. In addition, no better protection against SARS-CoV-2 infections
370 can be derived from the level of the antibody titre *per se*.

371 In summary, the administration of a vector vaccine followed by an mRNA vaccine boost resulted in a
372 strong humoral immune response, comparable to that after two immunisations with an mRNA vaccine.
373 Regardless of the vaccination scheme, all individuals developed highly avid anti-SARS-CoV-2 IgGs. Even
374 if almost all vaccinees presented VNA after the second immunisation, the generally lower titres
375 indicate a partial immune escape of the delta VOC.

376

377

378 **Availability of data:** The data presented in this study are available on request from the
379 corresponding author.

380 **Ethics approval and consent to participate:** The study was conducted according to the guidelines of
381 the Declaration of Helsinki, and approved by the Ethics Committee of the medical faculty of the
382 Christian-Albrechts-Universität zu Kiel, Kiel, Germany (D467/20, 16.04.2020; amendment 02.02.2021).
383 Informed consent was obtained from all subjects involved in the study.

384 **Consent for publication:** Not applicable.

385 **Competing interests:** The companies Diasorin GmbH, Mikrogen GmbH and Tecomedical GmbH
386 supported this study by providing free or discounted kits. None of the three companies had any
387 influence on the testing and the interpretation of the results. The authors declare that they have no
388 competing interests.

389 **Author Contributions:** AK, FN, and RR had full access to all the data in the study and take responsibility
390 for the integrity of the data and the accuracy of the data analysis. Concept and design: AK. Acquisition,
391 analysis, or interpretation of the data: all authors. Drafting of the manuscript: AK, HF and RR. Critical
392 revision of the manuscript for important intellectual content: all authors. All authors have read and
393 agreed to the published version of the manuscript.

394 **Funding:** This research received no external funding.

395 **Acknowledgments:** The authors would like to thank all volunteers for participating in the study.

396

397

398 References

- 399 1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol.*
400 2021;19(3):141-54. doi:10.1038/s41579-020-00459-7.
- 401 2. Klasse PJ, Nixon DF, Moore JP. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in
402 nonhuman primates and humans. *Sci Adv.* 2021;7(12). doi:10.1126/sciadv.abe8065.
- 403 3. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced
404 protection against COVID-19 in humans. *Nat Rev Immunol.* 2021;21(8):475-84. doi:10.1038/s41577-
405 021-00578-z.
- 406 4. Krammer F. SARS-CoV-2 vaccines in development. *Nature.* 2020;586(7830):516-27.
407 doi:10.1038/s41586-020-2798-3.
- 408 5. Cines DB, Bussel JB. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. *N Engl J*
409 *Med.* 2021;384(23):2254-6. doi:10.1056/NEJMe2106315.
- 410 6. Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies:
411 a comprehensive review of phase 3 candidates. *NPJ Vaccines.* 2021;6(1):28. doi:10.1038/s41541-021-
412 00292-w.
- 413 7. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. *JAMA.* 2021;325(13):1318-20.
414 doi:10.1001/jama.2021.3199.
- 415 8. EU. Safe COVID-19 vaccines for Europeans. 2021. [https://ec.europa.eu/info/live-work-travel-](https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en)
416 [eu/coronavirus-response/safe-covid-19-vaccines-europeans](https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/safe-covid-19-vaccines-europeans_en) en. Accessed 12 May 2021.
- 417 9. STIKO. Stellungnahme der Ständigen Impfkommission zum Zeitpunkt der Gabe eines mRNA-
418 Impfstoffs nach Erstimpfung mit AstraZeneca Vaccine (Vaxzevria) bei <60-Jährigen. 2021.
419 [https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-](https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-Impfabstand.html)
420 [Impfabstand.html](https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-Impfabstand.html). Accessed 12 May 2021.
- 421 10. RKI. Mitteilung der Ständigen Impfkommission beim Robert Koch-Institut Beschluss der STIKO zur
422 7. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung.
423 *Epidemiologisches Bulletin.* 2021;25:3-13.
- 424 11. Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C et al. A dynamic nomenclature
425 proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol.* 2020;5(11):1403-7.
426 doi:10.1038/s41564-020-0770-5.
- 427 12. STIKO. Mitteilung der STIKO zur COVID-19-Impfung: Impfabstand und heterologes Impfschema
428 nach Erstimpfung mit Vaxzevria (1.7.2021). 2021.
429 https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM_2021-07-01.html.
430 Accessed 2 July 2021.
- 431 13. Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K et al. Heterologous
432 vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune
433 responses in mice. *Nat Commun.* 2021;12(1):2893. doi:10.1038/s41467-021-23173-1.
- 434 14. He Q, Mao Q, An C, Zhang J, Gao F, Bian L et al. Heterologous prime-boost: breaking the protective
435 immune response bottleneck of COVID-19 vaccine candidates. *Emerg Microbes Infect.* 2021;10(1):629-
436 37. doi:10.1080/22221751.2021.1902245.
- 437 15. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD et al. Heterologous prime-
438 boost COVID-19 vaccination: initial reactogenicity data. *Lancet.* 2021;397(10289):2043-6.
439 doi:10.1016/S0140-6736(21)01115-6.

- 440 16. Groß R, Zaroni M, Seidel A, Conzelmann C, Gilg A, Krnavek D et al. Heterologous ChAdOx1 nCoV-
441 19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell
442 reactivity. medRxiv. 2021:2021.05.30.21257971. doi:10.1101/2021.05.30.21257971.
- 443 17. Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C et al. Safety, reactogenicity,
444 and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1
445 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021. doi:10.1016/S2213-
446 2600(21)00357-X.
- 447 18. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S et al. Immunogenicity and reactogenicity
448 of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nature Medicine. 2021. doi:10.1038/s41591-
449 021-01464-w.
- 450 19. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ et al. Safety and immunogenicity of
451 heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA
452 COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021.
453 doi:10.1016/S0140-6736(21)01694-9.
- 454 20. Normark J, Vikstrom L, Gwon YD, Persson IL, Edin A, Bjorsell T et al. Heterologous ChAdOx1 nCoV-
455 19 and mRNA-1273 Vaccination. N Engl J Med. 2021. doi:10.1056/NEJMc2110716.
- 456 21. Borobia AM, Carcas AJ, Perez-Olmeda M, Castano L, Bertran MJ, Garcia-Perez J et al.
457 Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants
458 (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet.
459 2021;398(10295):121-30. doi:10.1016/S0140-6736(21)01420-3.
- 460 22. Neumann F, Rose R, Rompke J, Grobe O, Lorentz T, Fickenscher H et al. Development of SARS-CoV-
461 2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination.
462 Vaccines (Basel). 2021;9(7):700. doi:10.3390/vaccines9070700.
- 463 23. Bonelli F, Blocki FA, Bunnell T, Chu E, De La OA, Grenache DG et al. Evaluation of the automated
464 LIAISON((R)) SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab
465 Med. 2021;59(8):1463-7. doi:10.1515/cclm-2021-0023.
- 466 24. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K et al. WHO International
467 Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347-8. doi:10.1016/S0140-
468 6736(21)00527-4.
- 469 25. Stromer A, Rose R, Grobe O, Neumann F, Fickenscher H, Lorentz T et al. Kinetics of Nucleo- and
470 Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2
471 Infection. Microorganisms. 2020;8(10). doi:10.3390/microorganisms8101572.
- 472 26. Stromer A, Rose R, Schafer M, Schon F, Vollersen A, Lorentz T et al. Performance of a Point-of-Care
473 Test for the Rapid Detection of SARS-CoV-2 Antigen. Microorganisms. 2020;9(1).
474 doi:10.3390/microorganisms9010058.
- 475 27. Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M et al. SARS-CoV-2 vaccines
476 for all but a single dose for COVID-19 survivors. EBioMedicine. 2021;68.
477 doi:10.1016/j.ebiom.2021.103401.
- 478 28. Struck F, Schreiner P, Staschik E, Wochinz-Richter K, Schulz S, Soutschek E et al. Vaccination versus
479 infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity
480 maturation. J Med Virol. 2021. doi:10.1002/jmv.27270.

- 481 29. Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R et al. COVID-19
482 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nature
483 Communications. 2021;12(1):3991. doi:10.1038/s41467-021-24285-4.
- 484 30. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM et al. Reduced sensitivity
485 of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276-80.
486 doi:10.1038/s41586-021-03777-9.
- 487 31. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C et al. Neutralising antibody activity against
488 SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331-3.
489 doi:10.1016/S0140-6736(21)01290-3.

490

491